Regeneron Pharma (REGN) PT Raised to $740 at Cantor Fitzgerald

Cantor Fitzgerald analyst Carter Gould raised the price target on Regeneron Pharma (NASDAQ: REGN) to $740.00 (from $678.00) while maintaining a Overweight rating.

The analyst commented, "Going into earnings, REGN had compelling valuation support – even if clarity on Eylea HD regulatory timelines was lacking. To Regeneron’s credit, it was able to get an FDA action date for a new fill/finish facility before YE25, opening up multiple pathways for the Eylea label extensions to play out over YE25-1H26E – far sooner than many had feared, and no longer dependent on Catalent (affiliate of NVO; NC). Those approvals are not a foregone conclusion, but we see this as drastically improving the odds of avoiding a second year without EPS growth."

You May Also Be Interested In

• Canaccord Downgrades York Space Systems (YSS) to Hold, 'Supply chain and contract timing uncertainty'
• Seaport Global Securities Downgrades JetBlue Airways (JBLU) to Neutral
• Tesla to launch Cybercab in Austin this month - report